Treatment of murine Th1- and Th2-mediated inflammatory bowel disease with NF-κB decoy oligonucleotides

Journal of Clinical Investigation

Volumn 115, Issue 11, 2005, Pages 3057-3071

  Fichtner Feigl, Stefan ^a   Fuss, Ivan J ^a   Preise, Jan C ^a   Strober, Warren ^a   Kitani, Atsushi ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DECOY OLIGONUCLEOTIDE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; LIPOCORTIN 5; OLIGONUCLEOTIDE; OXAZOLONE; PROTEIN P70; SYNAPTOTAGMIN; TRANSCRIPTION FACTOR REL; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG POTENCY; ENTERITIS; FIBROSIS; MOUSE; NONHUMAN; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; TRANSCRIPTION REGULATION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; DNA; FEMALE; FIBROSIS; GENETIC VECTORS; INFLAMMATORY BOWEL DISEASES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MUCOUS MEMBRANE; NF-KAPPA B; OLIGODEOXYRIBONUCLEOTIDES; SENDAI VIRUS; TH1 CELLS; TH2 CELLS;

EID: 27644453163     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI24792     Document Type: Article

References (67)

1. Podolsky, D.K. 2002. Inflammatory bowel disease. N. Engl. J. Med. 347:417-429.
2. Bouma, G., and Strober, W. 2003. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3:521-533.
3. Sartor, R.B. 2004. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology. 126:1620-1633.
4. Maeda, S., et al. 2005. Nod2 mutation in Crohn's disease potentiates NF-κ activity and IL-1β processing. Science. 307:734-738.
5. Heller, F., Fuss, I.J., Nieuwenhuis, E.E., Blumberg, R.S., and Strober, W. 2002. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity. 17:629-638.
6. Uhlig, H.H., and Powrie, F. 2003. Dendritic cells and the intestinal bacterial flora: a role for localized mucosal immune responses. J. Clin. Invest. 112:648-651. doi:10.1172/JCI200319545.
7. Monteleone, G., et al. 1997. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology. 112:1169-1178.
8. Mannon, P.J., et al. 2004. Anti-interleukin-12 antibody for active Crohn's disease. N. Engl. J. Med. 351:2069-2079.
9. Fuss, I.J., et al. 2004. Nonclassical CD1d-restricted NKT cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J. Clin. Invest. 113:1490-1497. doi:10.1172/JCI200419836.
10. Schmidt, C., et al. 2005. Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis. Inflamm. Bowel Dis. 11:16-23.
11. Neurath, M.F., Fuss, I., Kelsall, B.L., Stuber, E., and Strober, W. 1995. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med. 182:1281-1290.
12. Kitani, A., et al. 2000. Treatment of experimental (Trinitrobenzene sulfonic acid) colitis by intranasal administration of transforming growth factor (TGF)-beta1 plasmid: TGF-beta1-mediated suppression of T helper cell type 1 response occurs by interleukin (IL)-10 induction and IL-12 receptor beta2 chain downregulation. J. Exp. Med. 192:41-52.
13. Fuss, I.J., et al. 1999. Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology. 117:1078-1088.
14. Strober, W., Fuss, I.J., and Blumberg, R.S. 2002. The immunology of mucosal models of inflammation. Annu. Rev. Immunol. 20:495-549.
15. Boirivant, M., Fuss, I.J., Chu, A., and Strober, W. 1998. Oxazolone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J. Exp. Med. 188:1929-1939.
16. Neurath, M.F., Pettersson, S., Meyer zum Buschenfelde, K.H., and Strober, W. 1996. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat. Med. 2:998-1004.
17. Neurath, M.F., et al. 1998. Cytokine gene transcription by NF-kappa B family members in patients with inflammatory bowel disease. Ann. N. Y. Acad. Sci. 859:149-159.
18. Schreiber, S., Nikolaus, S., and Hampe, J. 1998. Activation of nuclear factor kappa B inflammatory bowel disease. Gut. 42:477-484.
19. Bantel, H., et al. 2000. Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am. J. Gastroenterol. 95:3452-3457.
20. Plevy, S.E., Gemberling, J.H., Hsu, S., Dorner, A.J., and Smale, S.T. 1997. Multiple control elements mediate activation of the murine and human interleukin 12 p40 promoters: evidence of functional synergy between C/EBP and Rel proteins. Mol. Cell. Biol. 17:4572-4588.
21. Becker, C., et al. 2003. Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. J. Clin. Invest. 112:693-706. doi:10.1172/JCI200317464.
22. Hilliard, B.A., et al. 2002. Critical roles of c-Rel in autoimmune inflammation and helper T cell differentiation. J. Clin. Invest. 110:843-850. doi: 10.1172/JCI200215254.
23. Zhang, Z., et al. 2005. Interleukin-1beta and tumor necrosis factor-alpha upregulate interleukin-23 subunit p19 gene expression in human colonic subepithelial myofibroblasts. Int. J. Mol. Med. 15:79-83.
24. Das, J., et al. 2001. A critical role for NF-kappa B in GATA3 expression and TH2 differentiation in allergic airway inflammation. Nat. Immunol. 2:45-50.
25. Schnare, M., et al. 2001. Toll-like receptors control activation of adaptive immune responses. Nat. Immunol. 2:947-950.
26. Pahl, A., Zhang, M., Kuss, H., Szelenyi, I., and Brune, K. 2002. Regulation of IL-13 synthesis in human lymphocytes: implications for asthma therapy. Br. J. Pharmacol. 135:1915-1926.
27. Lawrance, I.C., et al. 2003. A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-kappa B. Gastroenterology. 125:1750-1761.
28. Li, Q., and Verma, I.M. 2002. NF-kappaB regulation in the immune system. Nat. Rev. Immunol. 2:725-734.
29. Kotani, H., Nakajima, T., Lai, S., Morishita, R., and Kaneda, Y. 2004. The HVJ-envelope as an innovative vector system for cardiovascular disease. Curr. Gene Ther. 4:183-194.
30. Morishita, R., et al. 1997. In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction. Nat. Med. 3:894-899.
31. Tomita, N., Ogihara, T., and Morishita, R. 2003. Transcription factors as molecular targets: molecular mechanisms of decoy ODN and their design. Curr. Drug Targets. 4:603-608.
32. Gambari, R. 2004. New trends in the development of transcription factor decoy (TFD) pharmacotherapy. Curr. Drug Targets. 5:419-430.
33. Kaneda, Y., et al. 2002. Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol. Ther. 6:219-226.
34. Shimamura, M., et al. 2004. Novel therapeutic strategy to treat brain ischemia: overexpression of hepatocyte growth factor gene reduced ischemic injury without cerebral edema in rat model. Circulation. 109:424-431.
35. Tominaga, N., et al. 2003. Development of Th1 and not Th2 immune responses in mice lacking IFN-regulatory factor-4. Int. Immunol. 15:1-10.
36. Hu, C.M., Jang, S.Y., Fanzo, J.C., and Pernis, A.B. 2002. Modulation of T cell cytokine production by interferon regulatory factor-4. J. Biol. Chem. 277:49238-49246.
37. Saeki, Y., et al. 1997. Development and characterization of cationic liposomes conjugated with HVJ (Sendai virus): reciprocal effect of cationic lipid for in vitro and in vivo gene transfer. Hum. Gene Ther. 8:2133-2141.
38. Papa, S., Zazzeroni, F., Pham, G.G., Bubici, C., and Franzoso, G. 2004. Linking JNK signaling to NF-kappaB: a key to survival. J. Cell Sci. 117:5197-5208.
39. Tang, G., et al. 2001. Inhibition of JNK activation through NF-kappaB target genes. Nature. 414:313-317.
40. Stehlik, C., de Martin, R., Binder, B.R., and Lipp, J. 1998. Cytokine induced expression of porcine inhibitor of apoptosis protein (iap) family member is regulated by NF-kappa B. Biochem. Biophys. Res. Commun. 243:827-832.
41. Watanabe, T., Kitani, A., Murray, P.J., and Strober, W. 2004. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat. Immunol. 5:800-808.
42. Lawrence, T., Gilroy, D.W., Colville-Nash, P.R., and Willoughby, D.A. 2001. Possible new role for NF-kappaB in the resolution of inflammation. Nat. Med. 7:1291-1297.
43. Tomita, T., et al. 1999. Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor kappaB decoy oligodeoxynucleotides as a gene therapy. Arthritis Rheum. 42:2532-2542.
44. Suzuki, J., Morishita, R., Amano, J., Kaneda, Y., and Isobe, M. 2000. Decoy against nuclear factor-kappa B attenuates myocardial cell infiltration and arterial neointimal formation in murine cardiac allografts. Gene Ther. 7:1847-1852.
45. Ogushi, I., et al. 2003. Nuclear factor kappa B decoy oligodeoxynucleotides prevent endocoxin-induced fatal liver failure in a murine model. Hepatology. 38:335-344.
46. Kim, K.W., et al. 2005. Increased interleukin-17 production via a phosphoinositide 3-kinase/Akt and nuclear factor kappaB-dependent pathway in patients with rheumatoid arthritis. Arthritis Res. Ther. 7:R139-R148.
47. Kim, S.W., et al. 2004. Catalposide, a compound isolated from catalpa ovata, attenuates induction of intestinal epithelial proinflammatory gene expression and reduces the severity of trinitrobenzene sulfonic acid-induced colitis in mice. Inflamm. Bowel Dis. 10:564-572.
48. Matsumoto, S., et al. 2004. Fucoidan derived from cladosiphon okamuranus tokida ameliorates murine chronic colitis through the down-regulation of interleukin-6 production on colonic epithelial cells. Clin. Exp. Immunol. 136:432-439.
49. Sugimoto, K., et al. 2002. Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Gastroenterology. 123:1912-1922.
50. Hollenbach, E., et al. 2004. Inhibition of p38 MAP kinase- and RICK/NF-kappaB-signaling suppresses inflammatory bowel disease. FASEB J. 18:1550-1552.
51. Segain, J.P., et al. 2003. Rho kinase blockade prevents inflammation via nuclear factor kappa B inhibition: evidence in Crohn's disease and experimental colitis. Gastroenterology. 124:1180-1187.
52. Takagi, T., et al. 2002. Pioglitazone, a PPAR-gamma ligand, provides protection from dextran sulfate sodium-induced colitis in mice in association with inhibition of the NF-kappaB-cytokine cascade. Redox Rep. 7:283-289.
53. Herfarth, H., et al. 2000. Nuclear factor-kappa B activity and intestinal inflammation in dextran sulphate sodium (DSS)-induced colitis in mice is suppressed by gliotoxin. Clin. Exp. Immunol. 120:59-65.
54. Zhou, Y., et al. 2003. Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. Science. 302:1215-1217.
55. Hirooka, Y., Shimokawa, H., and Takeshita, A. 2004. Rho-kinase, a potential therapeutic target for the treatment of hypertension. Drug News Perspect. 17:523-527.
56. Hashimoto, K., et al. 2002. Suppression of airway hyperresponsiveness induced by ovalbumin sensitisation and RSV infection with Y-27632, a Rho kinase inhibitor. Thorax. 57:524-527.
57. Russell, F.D., and Molenaar, P. 2004. Investigation of signaling pathways that mediate the inotropic effect of urotensin-II in human heart. Cardiovasc. Res. 63:673-681.
58. Kweon, Y.O., et al. 2003. Gliotoxin-mediated apoptosis of activated human hepatic stellate cells. J. Hepatol. 39:38-46.
59. Waring, P., Sjaarda, A., and Lin, Q.H. 1995. Gliotoxin inactivates alcohol dehydrogenase by either covalent modification or free radical damage mediated by redox cycling. Biochem. Pharmacol. 49:1195-1201.
60. Vulcano, M., et al. 2001. Dendritic cells as a major source of macrophage-derived chemokine/CCL22 in vitro and in vivo. Eur. J. Immunol. 31:812-822.
61. Nakayama, T., et al. 2004. Selective induction of Th2-attracting chemokines CCL17 and CCL22 in human B cells by latent membrane protein 1 of Epstein-Barr virus. J. Virol. 78:1665-1674.
62. Berin, M.C., Dwinell, M.B., Eckmann, L., and Kagnoff, M.F. 2001. Production of MDC/CCL22 by human intestinal epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. 280:G1217-G1226.
63. Elewaut, D., et al. 2003. NIK-dependent RelB activation defines a unique signaling pathway for the development of V alpha 14i NKT cells. J. Exp. Med. 197:1623-1633.
64. Lee, C.G., et al. 2001. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J. Exp. Med. 194:809-821.
65. Kitani, A., et al. 2003. Transforming growth factor (TGF)-beta1-producing regulatory T cells induce Smad-mediated interleukin 10 secretion chat facilitates coordinated immunoregulatory activity and amelioration of TGF-beta1-mediated fibrosis. J. Exp. Med. 198:1179-1188.
66. Atreya, R., et al. 2000. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat. Med. 6:583-588.
67. Boirivant, M., Strober, W., and Fuss, I.J. 2005. Regulatory cells induced by feeding TNP-haptenated colonic protein cross-protect mice from colitis induced by an unrelated hapten. Inflamm. Bowel Dis. 1:48-55.